Company Overview

NeoChord, Inc.

Leading the advancement of transapical beating heart mitral valve repair for degenerative mitral regurgitation, NeoChord, Inc. is a privately-held global medical technology company, founded in 2007. NeoChord received CE market clearance in December 2012 for its DS1000 artificial chordae delivery system which has successfully treated over 450 patients to date.


NeoChord is based in St. Louis Park, Minnesota.